Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro

A drug-resistant cell line (EAC/Dox) was developed by repeated exposure of Ehrllch ascltes carcinoma cells to Doxorubicin (Dox) In vivo In male albino Swiss mice (6-8 weeks old). The weekly l.p. Injections of Dox to mice (2 or 4 mg/kg/week for 4 months) gave rise to Dox-reslstant cell line EAC/Dox,...

Ausführliche Beschreibung